Please enable JavaScript to continue using this application.

Compare $KROS vs $PYXS | Chartloom

Compare

$KROS vs $PYXS

Keros Therapeutics Inc · Pyxis Oncology Inc

KROS

Keros Therapeutics Inc

PYXS

Pyxis Oncology Inc

Compare $KROS vs $PYXS

Comparing Keros Therapeutics Inc and Pyxis Oncology Inc

KROSKeros Therapeutics Inc

PYXSPyxis Oncology Inc

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

PYXSPyxis Oncology Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-14.2%

YTD performance

76.5%

52W performance

-30.2%

FCF yield

-40.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KROS

PYXS

Detailed metrics comparison

KROS

Keros Therapeutics Inc

PYXS

Pyxis Oncology Inc

Market Cap

KROS$236M

PYXS$168M

Enterprise Value

KROS$-21M

PYXS$150M

Price

KROS$11.95

PYXS$2.03

P/E Ratio

KROSN/A

PYXSN/A

P/S Ratio

KROS15.75x

PYXS15.26x

EV/Sales

KROS-1.41x

PYXS13.55x

EV/EBITDA

KROS-0.47x

PYXS0.00x

P/B Ratio

KROS0.86x

PYXS15.60x

P/FCF Ratio

KROSN/A

PYXSN/A

EV/FCF

KROS0.44x

PYXS-2.20x

PEG Ratio

KROSN/A

PYXSN/A

Forward P/E (NTM)

KROSN/A

PYXSN/A

Forward P/S (NTM)

KROSN/A

PYXSN/A

Revenue (TTM)

KROS$15M

PYXS$11M

Revenue Growth (YoY)

KROS-93.6%

PYXS-14.2%

Forward Rev Growth

KROS-96.3%

PYXS14187.3%

Gross Margin (TTM)

KROS0.0%

PYXS78.4%

Operating Margin (TTM)

KROS0.0%

PYXS0.0%

EBITDA Margin (TTM)

KROS-665.2%

PYXS-580.0%

Net Margin (TTM)

KROS-553.9%

PYXS-593.0%

FCF Margin (TTM)

KROS-322.9%

PYXS-615.3%

Net Income (TTM)

KROS$-83M

PYXS$-65M

FCF (TTM)

KROS$-48M

PYXS$-68M

EPS (TTM)

KROS-$4.20

PYXS-$1.03

ROE (TTM)

KROS-2140.0%

PYXS-10177.0%

ROA (TTM)

KROS-1979.0%

PYXS-6981.0%

ROIC (TTM)

KROS-2140.0%

PYXS-10171.0%

Cash

KROS$258M

PYXS$19M

Debt

KROS$0

PYXS$0

Net Cash/Debt

KROS$258M

PYXS$19M

Current Ratio (TTM)

KROS21.96x

PYXS1.34x

Quick Ratio (TTM)

KROS21.53x

PYXS1.25x

Debt/Equity (TTM)

KROS0.00x

PYXS0.00x

Debt/Assets (TTM)

KROS0.0%

PYXS0.0%

Interest Coverage (TTM)

KROSN/A

PYXSN/A

Net Debt/EBITDA (TTM)

KROS0.00x

PYXS0.00x

Beta

KROS1.20

PYXS1.37

52W Performance

KROS-25.1%

PYXS-30.2%

YTD Performance

KROS-35.5%

PYXS76.5%

% from 52W High

KROS-47.0%

PYXS-63.4%

% from 52W Low

KROS23.3%

PYXS97.1%

Asset Turnover (TTM)

KROS0.06x

PYXS0.00x

FCF Yield (TTM)

KROS-20.5%

PYXS-40.3%

Earnings Yield (TTM)

KROS-35.2%

PYXS-38.9%

Dividend Yield (TTM)

KROSN/A

PYXSN/A

Rule of 40

KROS-416.5

PYXS-629.5

EV/GP/RG

KROSN/A

PYXS0.00

Ticker research

View KROS research View PYXS research

Metric	KROS Keros Therapeutics Inc	PYXS Pyxis Oncology Inc
Market & Valuation
Market Cap	$236M	$168M
Enterprise Value	$-21M	$150M
Price	$11.95	$2.03
P/E Ratio	N/A	N/A
P/S Ratio	15.75x	15.26x
EV/Sales	-1.41x	13.55x
EV/EBITDA	-0.47x	0.00x
P/B Ratio	0.86x	15.60x
P/FCF Ratio	N/A	N/A
EV/FCF	0.44x	-2.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$15M	$11M
Revenue Growth (YoY)	-93.6%	-14.2%
Forward Rev Growth	-96.3%	14187.3%
Profitability
Gross Margin (TTM)	0.0%	78.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-665.2%	-580.0%
Net Margin (TTM)	-553.9%	-593.0%
FCF Margin (TTM)	-322.9%	-615.3%
Net Income (TTM)	$-83M	$-65M
FCF (TTM)	$-48M	$-68M
EPS (TTM)	-$4.20	-$1.03
ROE (TTM)	-2140.0%	-10177.0%
ROA (TTM)	-1979.0%	-6981.0%
ROIC (TTM)	-2140.0%	-10171.0%
Financial Health
Cash	$258M	$19M
Debt	$0	$0
Net Cash/Debt	$258M	$19M
Current Ratio (TTM)	21.96x	1.34x
Quick Ratio (TTM)	21.53x	1.25x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.37
52W Performance	-25.1%	-30.2%
YTD Performance	-35.5%	76.5%
% from 52W High	-47.0%	-63.4%
% from 52W Low	23.3%	97.1%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.00x
FCF Yield (TTM)	-20.5%	-40.3%
Earnings Yield (TTM)	-35.2%	-38.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-416.5	-629.5
EV/GP/RG	N/A	0.00
Ticker research	View KROS research	View PYXS research

Valuation

P/S Ratio

PYXS

15.26x

KROS

15.75x

EV/FCF

PYXS

-2.20x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

PYXS

-14.2%

KROS

-93.6%

Forward Revenue Growth

PYXS

14187.3%

KROS

-96.3%

Profitability & performance

Gross Margin

PYXS

78.4%

KROS

0.0%

ROE

KROS

-2140.0%

PYXS

-10177.0%

FCF Yield %

KROS

-20.5%

PYXS

-40.3%

52-Week Performance

KROS

-25.1%

PYXS

-30.2%

Detailed metrics comparison

KROS

Keros Therapeutics Inc

PYXS

Pyxis Oncology Inc

Market Cap

KROS$236M

PYXS$168M

Enterprise Value

KROS$-21M

PYXS$150M

Price

KROS$11.95

PYXS$2.03

P/E Ratio

KROSN/A

PYXSN/A

P/S Ratio

KROS15.75x

PYXS15.26x

EV/Sales

KROS-1.41x

PYXS13.55x

EV/EBITDA

KROS-0.47x

PYXS0.00x

P/B Ratio

KROS0.86x

PYXS15.60x

P/FCF Ratio

KROSN/A

PYXSN/A

EV/FCF

KROS0.44x

PYXS-2.20x

PEG Ratio

KROSN/A

PYXSN/A

Forward P/E (NTM)

KROSN/A

PYXSN/A

Forward P/S (NTM)

KROSN/A

PYXSN/A

Revenue (TTM)

KROS$15M

PYXS$11M

Revenue Growth (YoY)

KROS-93.6%

PYXS-14.2%

Forward Rev Growth

KROS-96.3%

PYXS14187.3%

Gross Margin (TTM)

KROS0.0%

PYXS78.4%

Operating Margin (TTM)

KROS0.0%

PYXS0.0%

EBITDA Margin (TTM)

KROS-665.2%

PYXS-580.0%

Net Margin (TTM)

KROS-553.9%

PYXS-593.0%

FCF Margin (TTM)

KROS-322.9%

PYXS-615.3%

Net Income (TTM)

KROS$-83M

PYXS$-65M

FCF (TTM)

KROS$-48M

PYXS$-68M

EPS (TTM)

KROS-$4.20

PYXS-$1.03

ROE (TTM)

KROS-2140.0%

PYXS-10177.0%

ROA (TTM)

KROS-1979.0%

PYXS-6981.0%

ROIC (TTM)

KROS-2140.0%

PYXS-10171.0%

Cash

KROS$258M

PYXS$19M

Debt

KROS$0

PYXS$0

Net Cash/Debt

KROS$258M

PYXS$19M

Current Ratio (TTM)

KROS21.96x

PYXS1.34x

Quick Ratio (TTM)

KROS21.53x

PYXS1.25x

Debt/Equity (TTM)

KROS0.00x

PYXS0.00x

Debt/Assets (TTM)

KROS0.0%

PYXS0.0%

Interest Coverage (TTM)

KROSN/A

PYXSN/A

Net Debt/EBITDA (TTM)

KROS0.00x

PYXS0.00x

Beta

KROS1.20

PYXS1.37

52W Performance

KROS-25.1%

PYXS-30.2%

YTD Performance

KROS-35.5%

PYXS76.5%

% from 52W High

KROS-47.0%

PYXS-63.4%

% from 52W Low

KROS23.3%

PYXS97.1%

Asset Turnover (TTM)

KROS0.06x

PYXS0.00x

FCF Yield (TTM)

KROS-20.5%

PYXS-40.3%

Earnings Yield (TTM)

KROS-35.2%

PYXS-38.9%

Dividend Yield (TTM)

KROSN/A

PYXSN/A

Rule of 40

KROS-416.5

PYXS-629.5

EV/GP/RG

KROSN/A

PYXS0.00

Ticker research

View KROS research View PYXS research

Metric	KROS Keros Therapeutics Inc	PYXS Pyxis Oncology Inc
Market & Valuation
Market Cap	$236M	$168M
Enterprise Value	$-21M	$150M
Price	$11.95	$2.03
P/E Ratio	N/A	N/A
P/S Ratio	15.75x	15.26x
EV/Sales	-1.41x	13.55x
EV/EBITDA	-0.47x	0.00x
P/B Ratio	0.86x	15.60x
P/FCF Ratio	N/A	N/A
EV/FCF	0.44x	-2.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$15M	$11M
Revenue Growth (YoY)	-93.6%	-14.2%
Forward Rev Growth	-96.3%	14187.3%
Profitability
Gross Margin (TTM)	0.0%	78.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-665.2%	-580.0%
Net Margin (TTM)	-553.9%	-593.0%
FCF Margin (TTM)	-322.9%	-615.3%
Net Income (TTM)	$-83M	$-65M
FCF (TTM)	$-48M	$-68M
EPS (TTM)	-$4.20	-$1.03
ROE (TTM)	-2140.0%	-10177.0%
ROA (TTM)	-1979.0%	-6981.0%
ROIC (TTM)	-2140.0%	-10171.0%
Financial Health
Cash	$258M	$19M
Debt	$0	$0
Net Cash/Debt	$258M	$19M
Current Ratio (TTM)	21.96x	1.34x
Quick Ratio (TTM)	21.53x	1.25x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.37
52W Performance	-25.1%	-30.2%
YTD Performance	-35.5%	76.5%
% from 52W High	-47.0%	-63.4%
% from 52W Low	23.3%	97.1%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.00x
FCF Yield (TTM)	-20.5%	-40.3%
Earnings Yield (TTM)	-35.2%	-38.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-416.5	-629.5
EV/GP/RG	N/A	0.00
Ticker research	View KROS research	View PYXS research